

COPLEY HOSPITAL, INC.
FY2019 PROPOSED BUDGET
RESPONSE TO QUESTIONS FROM THE OFFICE OF THE HEALTH CARE ADVOCATE

- 1. Please provide by payer (Medicare, Medicaid, BCBSVT, TVHP, MVP, and Cigna):**
 - a. Your budgeted net patient revenue (NPR) and proposed NPR change from FY2019.**
 - b. The formula(s) you used to calculate your budgeted NPR, the definition of each variable in the formula(s), and the budgeted value of each variable for FY2020.**
 - c. The average ratio of the payer’s reimbursement rate to Medicare’s reimbursement rate.**

Following is a summary of the average ratio of each major payer source’s reimbursement rate as compared to Medicare:

| Payer | BUD19 | BUD20 | Change | Ratio to Medicare |
|------------------|--------------|--------------|---------------|--------------------------|
| Medicare | 21,074,124 | 23,267,114 | 2,192,990 | 1.00 |
| Medicaid w DSH | 6,163,403 | 6,735,763 | 572,360 | 0.85 |
| BCBSVT | 23,451,056 | 22,840,346 | (610,710) | 1.69 |
| Other Commercial | 16,865,879 | 17,143,651 | 277,772 | 1.56 |
| Workers’ Comp | 2,121,179 | 1,999,753 | (121,426) | 1.43 |
| Self pay | 525,674 | 671,735 | 146,061 | 0.64 |
| Total | 70,201,316 | 72,658,362 | 2,457,046 | 1.25 |

Please refer to Copley Hospital’s budget narrative, section 4.A.iv, for an explanation of net patient revenue assumptions by payer. Regrettably, we cannot reasonably provide each variable of the NPR estimates for each payer in a narrative format given the complexity of critical access reimbursement modeling calculations and contractual obligations to keep individual commercial payer reimbursement rates confidential.

- 2. Please delineate the hospital's financial performance and patient distribution by capitated business, fee for service business, and any other payment methodologies. (If you only have one type of business please state which type.)**
 - a. Please indicate which entities the hospital has capitated or other alternative payment agreements with (e.g., insurer(s), ACO).**

Copley Hospital receives a capitation payment from Medicaid for the Women’s Health Initiative, funded through the Blueprint for Health. Copley does not currently have any other agreements with insurers or ACOs that reimburse based on capitation or any other alternative payment methodologies. Copley has signed a letter of intent to participate in OneCare’s 2020 Risk-Based ACO Program for our Medicaid population. OneCare will supply us with a Participation Agreement this summer, along with a financial model to help support further decision making. A commitment to participate or not will be made in August.

- 3. Please describe any initiatives that you have implemented to address the inadequate access to mental health treatment experienced by Vermonters.**
 - a. What other avenues are you pursuing to address this crisis in a sustainable way?**

Copley Hospital’s Emergency Department (ED) will admit patients for medical stabilization that have a secondary need for mental health care; an overdose patient is a good example. Our care model relies on our partnerships with Lamoille County Mental Health and other regional agencies to provide crisis intervention for this population. In FY19, Copley finalized a new relationship with the Recovery Coaching Program provided by North

Central Vermont Recovery Center. The Recovery Coaching Program offers an alternative approach to support those that are or who wish to be in recovery. This partnership uses a peer coaching model and will be available to patients in the Emergency Department that are identified or request needing assistance with substance use. While this program is in its infancy, we have already connected more than a dozen patients to the coaching service, many of them who are now participating in outpatient support groups. The Recovery Coaching Program will be expanding the role of the peer coach this year to include providing patient and family education in the use of naloxone (Narcan) for opioid overdose rescue. In this expanded role, the recovery coach will be able to provide naloxone to patients, family, and/or friends through state funded programs in order to facilitate rescue efforts for unintentional opioid overdoses.

Copley Hospital and Community Health Services of Lamoille Valley (CHSLV) continue to partner to fund the position of "Community Referral Specialist." The referral specialist position is designed to support activities such as screening and to ensure timely follow-up and tracking of patients that have been referred to a Primary Care Provider (PCP) and/or community agency for treatment and/or services. The Community Referral Specialist works collaboratively with Lamoille County Mental Health and Behavioral Health & Wellness Center and is often able to continue to be available to follow the patient throughout the first few weeks of their recovery.

Copley Hospital completed renovation on an existing ED treatment room to provide a more safe and therapeutic environment for our patients that require one-on-one observation. Currently internal staff across the hospital provide this one-on-one supervision. In FY19, Management of Aggressive Behavior (MOAB) training has been provided to 74 staff members and will continue to be offered.

4. Please provide data on substance use treatment at your hospital, including:

- a. The number of patients currently enrolled in medication-assisted treatment at your hospital,**
- b. The number of MAT providers employed by your hospital, and**
- c. Other avenues that you are pursuing to address this crisis in a sustainable way.**

Copley Hospital collaborates with community partners to coordinate referrals for patients who wish to receive Medication Assisted Treatment (MAT). Patients from the Emergency Department (ED) and Inpatient areas are referred to MAT if appropriate as part of our standard discharge planning process.

Though Copley Hospital does not have an employed MAT provider or own any primary care practices, we have developed collaborative relationships with experts in the substance abuse field. Currently, Copley Hospital partners with Lamoille County Mental Health Alcohol and Substance Abuse Prevention (LCMH ASAP), Community Health Services of Lamoille Valley's (CHSLV) Medication Assisted Treatment (MAT) team, Treatment Associates and the BAART clinics. Our CMO attends regular meetings of the Healthy Valley Lamoille County Coalition to discuss community needs with key community leaders and clinicians. Our ED Referral Specialist also provides short-term case management until patients are able to get connected to appropriate MAT services.

5. Please provide the number of patient bed days attributable to patients awaiting placement in an appropriate Skilled Nursing Facility bed, and average bed days per patient, for:

- a. FY2018, and**
- b. FY2019 to date.**

Copley Hospital implemented a methodology for tracking delays in discharge or transfer during FY2019. From January 1st thru June 18th, there were 128 bed days attributable to patients awaiting placement in a Skilled Nursing Facility. After removing one outlier patient with uniquely complicated circumstances that attributed to 77 of those days, the average bed days per patient awaiting placement in a SNF during this time was 4 days.

6. Please provide the hospital’s per unit profit margin on each 340B drug dispensed and the number of units of each drug dispensed.

See Exhibit A below for a listing of Copley’s estimated per unit profit margin on each 340(b) drug dispensed and the number of units of each drug dispensed.

7. Please describe any changes to the hospital's shared-decision making programs.

- a. For any new initiatives, please describe the initiative(s), which departments participate, how you chose which departments participate, and how you plan to identify cost savings and quality improvement.**

Copley Hospital’s Orthopaedics practice, Mansfield Orthopaedics, has been practicing Shared Decision Making for several years, and continues to be a daily practice at Mansfield Orthopaedics. The Cardiology practice completed a shared decision-making study regarding treatment strategies for atrial fibrillation in FY18. The Cardiology study did not reflect any identifiable cost savings or significant quality improvement. At this time, we have not committed to implementing shared decision-making throughout the hospital system in 2020.

8. Please provide copies of your financial assistance policy, application, and plain language summary (noting any changes from your last submission).

- a. Please provide detailed information about the ways in which these three items can be obtained by patients, including links if they are available online.**
- b. Please provide the following data by year, 2014 to 2019 (to date):**
 - i. Number of people who were screened for financial assistance eligibility,**
 - ii. Number of people who applied for financial assistance,**
 - iii. Number of people who were granted financial assistance by level of financial assistance received,**
 - iv. Number of people who were denied financial assistance by reason for denial.**
 - v. Percentage of your patient population who received financial assistance.**
- c. Please provide the statistics and analyses you relied on to determine the qualification criteria, including any geographic restrictions, and the amount of assistance provided under your current financial assistance program. For example, analysis of financial need in the community and analysis of how much people can afford to pay.**

Copley’s financial assistance policy, application, and plan language summary are made widely available to patients and easily accessible at all hospital and clinic registration locations and on Copley’s website at <https://www.copleyvt.org/for-patients-and-visitors/billing-and-insurance/assistance-programs/>. Additionally, a short version of the financial assistance application is on the back of every patient statement.

Copley does not conduct upfront screening for presumptive eligibility for financial assistance as this time. Following is a summary of financial assistance application data from 2014 to 2019 (thru May 31, 2019):

| | FY14 | FY15 | FY16 | FY17 | FY18 | YTD19 May |
|------------------------------------|------|------|------|------|------|--------------|
| Applications Completed | 657 | 696 | 694 | 761 | 707 | 327 |
| Households Granted Aid | 645 | 681 | 676 | 739 | 684 | 313 |
| 100% Free Care | 568 | 628 | 632 | 699 | 635 | 288 |
| 75% Discount | 25 | 25 | 29 | 23 | 34 | 15 |
| 50% Discount | 15 | 9 | 15 | 17 | 15 | 12 |
| 25% Discount | 37 | 19 | n/a | n/a | n/a | n/a |
| Applications Rejected | 12 | 15 | 18 | 22 | 22 | 12 |
| Charity Care as % of Gross Revenue | 1.2% | 0.7% | 0.7% | 0.6% | 0.6% | 0.7% |

Copley does not track the detailed reasons for rejection of a financial assistance application, so we cannot provide that requested data. Anecdotally, we can share that the majority of rejected applications are for households that are over the income threshold. Occasionally an applicant is over the asset threshold (ie. balance of cash, investments, etc.).

The amount of financial assistance granted to eligible patients is determined on a sliding scale based on the household income. Free care is granted to eligible patients whose household income is at or below 300% of the Federal Poverty Level Guidelines (FPLG). Discounted care is granted to eligible patients whose household income is between 300% and 400% of the FPLG. Following is a table summarizing the amount of the discount granted to eligible patients based on the FPLG:

| FPLG | Up to 300% | 301%-350% | 351%-400% |
|----------|------------|-----------|-----------|
| Discount | 100% | 75% | 50% |

9. For the hospital’s inpatient services, please provide your total discharges, case mix adjusted discharges, all payer case mix index, and average cost per case mix adjusted discharge for 2014 (actual) through the present (2019 budget and projected) and 2020 (budget).

| | ACT14 | ACT15 | ACT16 | ACT17 | ACT18 | BUD19 | PROJ19 | BUD20 |
|---|----------|----------|----------|----------|----------|----------|----------|----------|
| Total Discharges | 1,795 | 1,980 | 1,994 | 2,025 | 2,009 | 2,137 | 2,084 | 2,055 |
| Case-Mix Adjusted Discharges | 1,903 | 2,277 | 2,373 | 2,471 | 2,612 | 2,693 | 2,855 | 2,815 |
| All-payer Case Mix Index | 1.06 | 1.15 | 1.19 | 1.22 | 1.30 | 1.26 | 1.37 | 1.37 |
| Gross price per Case-Mix Adj Discharges | \$14,768 | \$15,029 | \$15,017 | \$15,231 | \$14,371 | \$15,579 | \$14,810 | \$15,876 |

10. Last year the Board’s hospital budget orders instructed hospitals to negotiate with insurers rather than seeing the Board’s approval as a specific set rate. Please describe how you implemented this directive.

a. What average commercial rate increase did you implement for FY2019?

b. What commercial rate increase did you get from each commercial payer (BCBSVT, TVHP, MVP, Cigna)?

The GMCB approved a 4.5% increase in Copley’s average gross charges for FY19, bringing our cumulative rate change to a reduction of 6.6% since FY15. Our major commercial insurers were notified of this proposed change in rates, providing an opportunity to re-negotiate contract terms and/or implement the changes in any appropriate fee schedules. No commercial payer rejected the GMCB-approved change in average gross charges for FY19.

EXHIBIT A – 340(B) DRUG PER UNIT PROFIT (LOSS)

| NDC | Vendor Item Name | Units Dispensed | Estimated Profit(Loss) Per Unit |
|-------------|---|-----------------|---------------------------------|
| 00003029305 | Kenalog40MG/MLSUSP | 2 | (1.81) |
| 00006306100 | Emend150MGSOLR | 34 | (166.15) |
| 00006384371 | INVanz1GMSOLR | 13 | (255.36) |
| 00006542312 | Bridion200MG/2MLSOLN | 3 | (573.07) |
| 00008092360 | Protonix40MGSOLR | 2 | (46.12) |
| 00009082501 | Solu-CORTEF100MGSOLR | 4 | (0.01) |
| 00023114501 | Botox100UNITSOLR | 1 | (312.33) |
| 00052060202 | TiceBCG50MGSUSR | 8 | (82.80) |
| 00052433001 | Nexplanon68MGIMPL | 4 | (319.44) |
| 00054350049 | LidocaineViscousHCl2%SOLN | 2 | (1.11) |
| 00065074114 | TetracaineHCl0.5%SOLN | 2 | (82.34) |
| 00065853302 | Ciprodex0.3-0.1%SUSP | 2 | (29.15) |
| 00071101341 | Lyrica50MGCAPS | 3 | (25.14) |
| 00074334603 | LupronDepot(3-Month)22.5MGKIT | 4 | (258.83) |
| 00074347303 | LupronDepot(6-Month)45MGKIT | 3 | (256.39) |
| 00074364103 | LupronDepot(1-Month)3.75MGKIT | 3 | (70.97) |
| 00074364203 | LupronDepot(1-Month)7.5MGKIT | 5 | (86.31) |
| 00085432001 | CelestoneSoluspan6(3-3)MG/MLSUSP | 4 | (12.07) |
| 00093202631 | Azithromycin200MG/5MLSUSR | 8 | (5.72) |
| 00093314701 | Cephalexin500MGCAPS | 1 | (2.05) |
| 00115146860 | Lidocaine-Prilocaine2.5-2.5%CREA | 1 | (1.34) |
| 00121176230 | Mag-AlPlusXS400-400-40MG/5MLLIQD | 1 | (104.44) |
| 00143950610 | Etomidate2MG/MLSOLN | 1 | (16.07) |
| 00143962201 | LabetalolHCl5MG/MLSOLN | 1 | (2.02) |
| 00143970101 | IrinotecanHCl100MG/5MLSOLN | 8 | (7.81) |
| 00143987525 | AmiodaroneHCl150MG/3MLSOLN | 1 | (15.09) |
| 00143992490 | ceFAZolinSodium1GMSOLR | 2 | (11.81) |
| 00168008031 | Hydrocortisone2.5%CREA | 2 | (1.08) |
| 00173071920 | FloventHFA110MCG/ACTAERO | 1 | (0.10) |
| 00173072020 | FloventHFA220MCG/ACTAERO | 1 | (0.10) |
| 00264310511 | ceFAZolinSodium-Dextrose2-3GM-%(50ML)SOLR | 33 | (111.05) |
| 00338067104 | KClinDextrose-NaCl20-5-0.45MEQ/L-%SOLN | 6 | (15.64) |
| 00338105102 | NitroglycerininD5W400-5MCG/ML-%SOLN | 1 | (44.26) |
| 00409115901 | BupivacaineHCl(PF)0.25%SOLN | 3 | (10.98) |
| 00409198530 | LORazepam2MG/MLSOLN | 6 | (14.25) |
| 00409341401 | MetoclopramideHCl5MG/MLSOLN | 13 | (17.32) |
| 00409477702 | CiprofloxacininD5W400MG/200MLSOLN | 1 | (37.66) |
| 00409653102 | VancomycinHCl750MGSOLR | 2 | (19.64) |
| 00409662502 | SodiumBicarbonate8.4%SOLN | 1 | (131.25) |
| 00409733201 | cefTRIAxoneSodium1GMSOLR | 10 | (8.57) |

| | | | |
|-------------|--|----|----------|
| 00409909422 | fentaNYLCitrate(PF)100MCG/2MLSOLN | 61 | (8.23) |
| 00469305130 | AmBisome50MGSUSR | 5 | (194.24) |
| 00469650189 | Lexiscan0.4MG/5MLSOLN | 16 | (121.29) |
| 00487020101 | lpratropium-Albuterol0.5-2.5(3)MG/3MLSOLN | 8 | (5.93) |
| 00487950101 | AlbuterolSulfate(2.5MG/3ML)0.083%NEBU | 1 | (3.37) |
| 00517234010 | Venofer20MG/MLSOLN | 7 | (204.05) |
| 00536110888 | NicotineStep121MG/24HRPT24 | 3 | (3.34) |
| 00536111825 | ArthritisPainRelieving0.075%CREA | 1 | (2.53) |
| 00536741551 | Enema7-19GM/118MLENEM | 11 | (0.41) |
| 00548560500 | EnoxaparinSodium100MG/MLSOLN | 1 | (46.35) |
| 00574402235 | Bacitracin500UNIT/GMOINT | 3 | (37.01) |
| 00574704012 | BelladonnaAlkaloids-Opium16.2-60MGSUPP | 2 | (194.16) |
| 00597026010 | GlucaGenDiagnostic1MGSOLR | 20 | (23.58) |
| 00641036725 | DexamethasoneSodiumPhosphate10MG/MLSOLN | 1 | (15.54) |
| 00641611610 | Ampicillin-SulbactamSodium1.5(1-0.5)GMSOLR | 1 | (8.46) |
| 00641612525 | MorphineSulfate(PF)4MG/MLSOLN | 1 | (14.36) |
| 00641612725 | MorphineSulfate(PF)10MG/MLSOLN | 2 | (14.42) |
| 00703424401 | CARBOplatin50MG/5MLSOLN | 8 | (3.26) |
| 00703424601 | CARBOplatin150MG/15MLSOLN | 17 | (6.83) |
| 00703424801 | CARBOplatin450MG/45MLSOLN | 2 | (16.33) |
| 00703514001 | LeucovorinCalcium100MGSOLR | 7 | (0.01) |
| 00713052612 | Promethegan25MGSUPP | 2 | (11.69) |
| 00781577631 | Azithromycin250MGTABS | 3 | (13.87) |
| 00781604158 | Amoxicillin250MG/5MLSUSR | 9 | (0.54) |
| 00904198261 | Mapap325MGTABS | 19 | (0.27) |
| 00904386575 | DeepSeaNasalSpray0.65%SOLN | 3 | (0.39) |
| 00904571135 | NasalDecongestantSpray0.05%SOLN | 1 | (0.30) |
| 00904600961 | LORazepam2MGTABS | 1 | (2.67) |
| 00904644461 | oxyCODONEHCl5MGTABS | 1 | (5.40) |
| 00904646161 | PromethazineHCl25MGTABS | 1 | (5.81) |
| 00904646707 | ClopidogrelBisulfate300MGTABS | 1 | (5.87) |
| 00904647461 | PantoprazoleSodium40MGTBEC | 2 | (0.82) |
| 00904650261 | Celecoxib100MGCAPS | 6 | (59.91) |
| 00904651761 | MeclizineHCl25MGTABS | 1 | (16.99) |
| 00904780961 | CyclobenzaprineHCl10MGTABS | 1 | (2.84) |
| 00904782236 | ClotrimazoleAnti-Fungal1%CREA | 1 | (0.36) |
| 16729011431 | Etoposide100MG/5MLSOLN | 17 | (3.12) |
| 16729027668 | Fluorouracil500MG/10MLSOLN | 1 | (11.12) |
| 17478020102 | PhenylephrineHCl2.5%SOLN | 1 | (5.55) |
| 17478054202 | Adenosine6MG/2MLSOLN | 1 | (12.87) |
| 24208063562 | Neomycin-Polymyxin-HC3.5-10000-1SUSP | 1 | (8.24) |
| 24338013402 | E.E.S.Granules200MG/5MLSUSR | 1 | (116.92) |
| 25021021599 | Fluorouracil5GM/100MLSOLN | 9 | (13.83) |
| 25021040201 | HeparinSodium(Porcine)5000UNIT/MLSOLN | 2 | (15.96) |
| 25021060851 | Propofol1000MG/100MLEMUL | 5 | (77.32) |

| | | | |
|-------------|--|----|------------|
| 25021081530 | LeucovorinCalcium200MGSOLR | 9 | (8.25) |
| 25021082761 | IbandronateSodium3MG/3MLSOLN | 1 | (1.25) |
| 36000016210 | NorepinephrineBitartrate1MG/MLSOLN | 1 | (13.39) |
| 36000028225 | Furosemide10MG/MLSOLN | 3 | (20.59) |
| 39822400001 | levETIRAcetam500MG/5MLSOLN | 2 | (19.59) |
| 42023011310 | Ketalar10MG/MLSOLN | 1 | (86.67) |
| 42023015925 | Adrenalin1MG/MLSOLN | 2 | (0.20) |
| 43598020451 | Amoxicillin-PotClavulanate250-62.5MG/5MLSUSR | 2 | (9.49) |
| 49502010202 | EPINEPHrine0.3MG/0.3MLSOAJ | 8 | (0.04) |
| 50242004164 | CathfloActivase2MGSOLR | 12 | (29.34) |
| 50383018902 | Gatifloxacin0.5%SOLN | 3 | (7.12) |
| 50383077517 | LidocaineViscousHCl2%SOLN | 1 | (5.46) |
| 50419042301 | Mirena(52MG)20MCG/24HRIUD | 25 | (263.89) |
| 50419042401 | Kyleena19.5MGIUD | 1 | (452.32) |
| 51079072420 | ZolpidemTartrate5MGTABS | 1 | (1.13) |
| 51991014417 | MethylergonovineMaleate0.2MG/MLSOLN | 1 | (109.41) |
| 55150017030 | BupivacaineHCl(PF)0.5%SOLN | 6 | (21.14) |
| 55150019410 | EsmololHCl100MG/10MLSOLN | 1 | (43.07) |
| 55150020210 | PantoprazoleSodium40MGSOLR | 4 | (19.39) |
| 55513000404 | Aranesp(AlbuminFree)60MCG/MLSOLN | 1 | (532.68) |
| 55513071001 | Prolia60MG/MLSOSY | 8 | (544.77) |
| 55513073001 | Xgeva120MG/1.7MLSOLN | 24 | (1,111.89) |
| 55566280001 | Cervidil10MGINST | 13 | (110.26) |
| 57237001830 | DULoxetineHCl30MGCPEP | 1 | (1.70) |
| 57894003001 | Remicade100MGSOLR | 21 | (379.93) |
| 58160096412 | RabAvertSUSR | 10 | (223.06) |
| 59011041020 | OxyCONTIN10MGT12A | 3 | (4.88) |
| 59310057922 | ProAirHFA108(90Base)MCG/ACTAERS | 65 | (0.06) |
| 59365512801 | ParagardIntrauterineCopperIUD | 4 | (190.17) |
| 59676032004 | Procrit20000UNIT/MLSOLN | 1 | (483.99) |
| 59762453802 | medroxyPROGESTERoneAcetate150MG/MLSUSY | 17 | (14.38) |
| 60505613005 | OndansetronHCl4MG/2MLSOLN | 20 | (3.51) |
| 60505614904 | cefTRIAxoneSodium2GMSOLR | 2 | (16.92) |
| 60758080110 | TimololMaleate0.5%SOLN | 2 | (2.56) |
| 61314001601 | ProparacaineHCl0.5%SOLN | 39 | (11.07) |
| 61314054701 | Latanoprost05%SOLN | 5 | (2.26) |
| 61703034916 | IrinotecanHCl40MG/2MLSOLN | 2 | (4.32) |
| 62856079701 | Aloxi0.25MG/5MLSOLN | 37 | (54.83) |
| 63020004901 | Velcade3.5MGSOLR | 48 | (1,283.36) |
| 63323001201 | Oxytocin10UNIT/MLSOLN | 1 | (4.71) |
| 63323010365 | CISPlatin100MG/100MLSOLN | 5 | (12.49) |
| 63323016501 | DexamethasoneSodiumPhosphate4MG/MLSOLN | 10 | (12.36) |
| 63323018410 | FolicAcid5MG/MLSOLN | 1 | (10.14) |
| 63323018610 | SodiumChloride0.9%SOLN | 1 | (7.06) |
| 63323028635 | Naropin5MG/MLSOLN | 4 | (83.20) |

| | | | |
|-------------|--|---|----------|
| 63323037805 | OctreotideAcetate200MCG/MLSOLN | 2 | (24.30) |
| 63323048927 | Xylocaine-MPF/EPINEPHrine2%-1:200000SOLN | 1 | (31.96) |
| 63323056887 | EnoxaparinSodium40MG/0.4MLSOLN | 1 | (16.19) |
| 63323066401 | diphenhydrAMINEHCl50MG/MLSOLN | 1 | (13.49) |
| 63323076305 | PACLitaxel30MG/5MLCONC | 1 | (2.39) |
| 63323087115 | DAPTOmycin500MGSOLR | 9 | (96.05) |
| 63739043401 | AspirinLowStrength81MGCHEW | 1 | (6.41) |
| 63739044710 | PotassiumChlorideCrysER20MEQTBCR | 1 | (22.59) |
| 63739067210 | Ibuprofen400MGTABS | 1 | (3.73) |
| 63833038702 | Kcentra1000UNITKIT | 4 | (943.71) |
| 64679005601 | PiperacillinSod-TazobactamSo3.375(3-0.375)GMSOLR | 1 | (23.53) |
| 65862014736 | SUMAtriptanSuccinate50MGTABS | 2 | (1.13) |
| 66685100101 | Amoxicillin-PotClavulanate875-125MGTABS | 1 | (25.59) |
| 68084006901 | CiprofloxacinHCl250MGTABS | 1 | (8.79) |
| 68084070301 | Ibuprofen600MGTABS | 1 | (4.77) |
| 68094058862 | ChildrensAcetaminophen325MG/10.15MLSUSP | 1 | (16.21) |
| 68462015713 | Ondansetron4MGTBDP | 8 | (2.26) |
| 68462056417 | MupirocinCalcium2%CREA | 2 | (41.92) |
| 70069001125 | Glycopyrrolate0.2MG/MLSOLN | 2 | (58.74) |
| 70710101002 | OseltamivirPhosphate75MGCAPS | 2 | (21.10) |
| 70860010010 | Azithromycin500MGSOLR | 4 | (20.35) |
| 70860010520 | VancomycinHCl1GMSOLR | 4 | (28.82) |
| 70860030005 | MetoprololTartrate5MG/5MLSOLN | 4 | (7.36) |
| 76045000905 | Dilaudid1MG/MLSOLN | 8 | (0.20) |
| 76045000910 | Dilaudid1MG/MLSOLN | 5 | (0.20) |
| 76329301505 | LidocaineHClUrethral/Mucosal2%GEL | 1 | (119.02) |
| 76329330101 | Dextrose50%SOLN | 1 | (65.88) |
| 76329333901 | AtropineSulfate1MG/10MLSOSY | 1 | (58.51) |
| 76329336901 | NaloxoneHCl2MG/2MLSOSY | 2 | (209.50) |